nadofaragene firadenovec
Trade name: Adstiladrin
Gene therapyapprovedBreakthrough Therapy FDA
Approved
Dec 16, 2022
Clinical trial activity
6 trials · 2 clinical orgs · 1 marketing orgs
Phase 1
1
Phase 2
5
Phase 3
3
Phase 4
1
Earliest trial started Dec 21, 2022 (NCT05704244)
Timeline
Indications
Approved for
Mechanism of action
- Interferon alphaOTHER
Interferon alpha other
- Interferon alpha-17 (IFNA17) ↗
- Interferon alpha-4 (IFNA4) ↗
- Interferon alpha-14 (IFNA14) ↗
- Interferon alpha-6 (IFNA6) ↗
- Interferon alpha-8 (IFNA8) ↗
- Interferon alpha-5 (IFNA5) ↗
- Interferon alpha-10 (IFNA10) ↗
- Interferon alpha-2 (IFNA2) ↗
- Interferon alpha-1/13 (IFNA1; IFNA13) ↗
- Interferon alpha-7 (IFNA7) ↗
- Interferon alpha-21 (IFNA21) ↗
- Interferon alpha-16 (IFNA16) ↗
- Interferon alpha-2EXOGENOUS GENE
Interferon alpha-2 exogenous gene
Approval history
- approvedBreakthroughDec 16, 2022
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3990041 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06929286 | Phase 3 | Apr 11, 2025 | Memorial Sloan-Kettering Cancer Center |
| NCT06668493 | Phase 1/Phase 2 (Phase 2) | Nov 30, 2024 | Ferring |
| NCT06510374 | Phase 3 | Oct 1, 2024 | Ferring |
| NCT06545955 | Phase 2 | Oct 1, 2024 | Ferring |
| NCT06390111 | Phase 4 | Jun 17, 2024 | Ferring |
| NCT05704244 | Phase 3 | Dec 21, 2022 | Ferring |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ferring | For profit | 5 | 5 | 3 | 2022 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1